Immix Biopharma (IMMX) Profit After Tax (2021 - 2026)

Immix Biopharma has disclosed Profit After Tax across 6 years of filings, most recently posting -$10.1 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$10.1 million, down 122.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$35.0 million (down 67.19% YoY), and the FY2025 annual result was -$29.4 million, down 36.03% from the prior year.
• Profit After Tax came in at -$10.1 million for Q1 2026 at Immix Biopharma, up from -$10.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$1.3 million in Q1 2022 to a low of -$10.6 million in Q4 2025.
• The 5-year median for Profit After Tax is -$4.5 million (2025), against an average of -$5.0 million.
• Peak annual rise in Profit After Tax reached 83.3% in 2022, while the deepest fall reached 649.04% in 2022.
• Immix Biopharma's Profit After Tax stood at -$3.8 million in 2022, then plunged by 33.94% to -$5.1 million in 2023, then rose by 5.45% to -$4.8 million in 2024, then sank by 121.3% to -$10.6 million in 2025, then climbed by 5.28% to -$10.1 million in 2026.
• The last three Profit After Tax figures came in at -$10.1 million (Q1 2026), -$10.6 million (Q4 2025), and -$7.6 million (Q3 2025), per Business Quant data.